Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas
- 1 December 2005
- journal article
- Published by Wiley in Liver International
- Vol. 25 (6) , 1202-1208
- https://doi.org/10.1111/j.1478-3231.2005.01174.x
Abstract
About 10-30% of primary liver cancers represent intrahepatic cholangiocarcinomas (IHCC). Since chromosomal losses of 3p are detectable in about 40% of cholangiocarcinomas our study aimed at the identification of mechanisms leading to functional deletion of tumor suppressor genes in this region. Our efforts focussed on genomic losses and epigenetic inactivation of two tumor suppressor genes, the fragile histidine triad (FHIT) and the ras association domain family 1 (RASSF1A) genes, both located on the short arm of chromosome 3. Methylation-specific PCR (MSP) and combined bisulfite-dependent restriction analysis (COBRA) were applied to detect epigenetic silencing of gene promoters. Genomic duplex PCR was used to identify exon losses of the FHIT gene. Nineteen paraffin-embedded samples of intrahepatic cholangiocarcinomas were studied. Here we report for the first time that in addition to frequent losses of the exons 5 and 6, hypermethylation of the FHIT promoter occured in a significant portion of IHCC. Methylation specific PCR (MSP) detected epigenetic inactivation of the FHIT/FRA3B locus in 8 of 19 (42%) cases. Combined bisulfite restriction analysis (COBRA) revealed that high levels of methylated FHIT promoter sequences were present in 6 of the 8 methylation positive samples. In agreement with previous reports MSP identified hypermethylation of the RASSF1A gene in 13 of 19 (68%) IHCC specimens examined. Epigenetic silencing of the FHIT tumor suppressor gene is a novel inactivation mechanism to be considered in the development of intrahepatic cholangiocarcinomas. However, a statistically significant inverse correlation between K-Ras activation and RASSF1A inactivation was not found.Keywords
This publication has 27 references indexed in Scilit:
- Fhit is a physiological target of the protein kinase SrcProceedings of the National Academy of Sciences, 2004
- Association of FHIT (fragile histidine triad), a candidate tumour suppressor gene, with the ubiquitin-conjugating enzyme hUBC9Biochemical Journal, 2000
- Frequency of p16INK4A alterations and k-ras mutations in intrahepatic cholangiocarcinoma of the liverGut, 2000
- The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle controlProceedings of the National Academy of Sciences, 1999
- Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liverBritish Journal of Cancer, 1999
- Replacement of Fhit in cancer cells suppresses tumorigenicityProceedings of the National Academy of Sciences, 1997
- The FHIT Gene, Spanning the Chromosome 3p14.2 Fragile Site and Renal Carcinoma–Associated t(3;8) Breakpoint, Is Abnormal in Digestive Tract CancersCell, 1996
- Fhit, a Putative Tumor Suppressor in Humans, Is a Dinucleoside 5‘,5‘ ‘‘-P1,P3-Triphosphate HydrolaseBiochemistry, 1996
- Clinicopathologic spectrum of resected extraductal mass-forming intrahepatic cholangiocarcinomaCancer, 1995
- Surgical treatment of cholangiocellular carcinomaWorld Journal of Surgery, 1995